FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL Read more about FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA Read more about FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA
Amgen Announces New Data Being Presented At ASH 2021 Read more about Amgen Announces New Data Being Presented At ASH 2021
Amgen Announces 10% Increase In 2022 First Quarter Dividend Read more about Amgen Announces 10% Increase In 2022 First Quarter Dividend
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis Read more about Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse Read more about FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse
Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year Read more about Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year
Amgen To Present At The 2021 Evercore ISI Healthcare Conference Read more about Amgen To Present At The 2021 Evercore ISI Healthcare Conference
Amgen To Present At The 2021 Piper Sandler Healthcare Conference Read more about Amgen To Present At The 2021 Piper Sandler Healthcare Conference
Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge Read more about Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge
